Modulation of gut microbiota in targeted cancer therapy:insights on the EGFR/VEGF/KRAS pathways  

作　　者：Li Gong Shixue Yang Junli Huang Yongsheng Li 

机构地区：[1]Department of Phase I Clinical Trial Ward,Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment,Chongqing University Cancer Hospital,Chongqing 400030,China [2]Key Laboratory of Biorheological Science and Technology of Ministry of Education,Bioengineering College,Chongqing University,Chongqing 400044,China [3]Department of Medical Oncology,Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment,Chongqing University Cancer Hospital,Chongqing 400030,China

出　　处：《Cancer Biology & Medicine》2024年第12期1141-1155,共15页癌症生物学与医学(英文版)

基　　金：supported by the Major International(Regional)Joint Research Program of the National Natural Science Foundation of China(Grant No.81920108027);National Outstanding Youth Reserve Talent Training Project,Research Capacity Enhancement Project of Chongqing University Cancer Hospital(Grant No.Y121);Funding for Chongqing Young and Middle-Aged Medical Excellence Team.

摘　　要：The rise in the incidence of cancer globally has led to a heightened interest in targeted therapies as a form of anticancer treatment.Key oncogenic targets,including epidermal growth factor receptor(EGFR),vascular endothelial growth factor(VEGF),and kirsten rat sarcoma viral oncogene homologue(KRAS),have emerged as focal points in the development of targeted agents.Research has investigated the impact of gut microbiota on the efficacy of various anticancer therapies,such as immunotherapy,chemotherapy,and radiotherapy.However,a notable gap exists in the literature regarding the relationship between gut microbiota and targeted agents.This review emphasizes how specific gut microbiota and gut microbiota metabolites,including butyrate,propionate,and ursodeoxycholic acid,interact with oncogenic pathways to modulate anti-tumor effects.Conversely,deoxycholic acid,lipopolysaccharide,and trimethylamine n-oxide may exert pro-tumor effects.Furthermore,modulation of the gut microbiota influences glucose and lipid metabolism,thereby enhancing the response to anti-KRAS agents and addressing diarrhea induced by tyrosine kinase inhibitors.By elucidating the connection between gut microbiota and the EGFR/VEGF/KRAS pathways,this review provides valuable insights for advancing targeted cancer therapy and optimizing treatment outcomes in clinical settings.

关 键 词：Gut microbiota METABOLITES targeted therapy tumorigenesis pathway EGFR VEGF KRAS 

分 类 号：R73[医药卫生—肿瘤]